Cannalean Biotechs
CBD-based Solutions for Treating Dyslipidemia
Company Overview
Snapshot
Founded in March 2018 by David Bassa, Cannalean Biotechs operates with 1–10 employees. The company is focused on developing novel treatments, having recently completed a first-in-human feasibility study for its CBD-based lipid-lowering therapy in January 2026.
Business overview
Cannalean Biotechs is a Health Tech & Life Sciences company specializing in the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan. This formulation is designed to treat dyslipidemia by reducing lipid blood levels, offering a potential alternative to existing treatments. The company utilizes a synthetic, non-psychotropic form of CBD combined with biocompatible chitosan to enhance its efficacy. Cannalean Biotechs operates within the pharmaceuticals and medical cannabis sectors, targeting patients with metabolic diseases.
Strategic signal
In January 2026, Cannalean Biotechs announced the positive completion of a first-in-human feasibility study for its novel CBD-based lipid-lowering therapy. This milestone is a critical validation of the company's core technology, signaling significant progress in its clinical development pipeline and de-risking its therapeutic approach for investors and potential partners in the pharmaceutical and medical cannabis industries.
Log in to access full profile ›Company Intelligence Q&A
- What is Cannalean Biotechs' primary focus?
- Cannalean Biotechs is focused on the research and development of a proprietary formulation combining cannabidiol (CBD) and chitosan for the treatment of dyslipidemia, aiming to reduce lipid blood levels.
- When was Cannalean Biotechs founded?
- Cannalean Biotechs was founded in March 2018.
- What was the outcome of the recent clinical study?
- In January 2026, Cannalean Biotechs announced the positive completion of a first-in-human feasibility study for its novel CBD-based lipid-lowering therapy.
- What is the strategic significance of the CBD and chitosan formulation?
- The formulation uses a synthetic, non-psychotropic CBD combined with chitosan to enhance its potential for reducing cholesterol and triglyceride levels, positioning it as a potential alternative to existing stain treatments with fewer risks.
- What was a key development in June 2022?
- In June 2022, Cannalean Biotechs announced a Phase 2a clinical trial for its cannabidiol-based formulation aimed at lowering blood cholesterol levels.